Dr Wei Hong Wang and colleagues systematically assessed the efficacy of proton pump inhibitors (PPIs) in the treatment of functional dyspepsia vs. placebo.
The investigative team determined if any difference in the response exists between symptom subgroups of functional dyspepsia.
The team performed a literature search through 2005 in PubMed, Medline, Embase, CINAHL, and Cochrane databases.
|The estimated number needed to treat was 15|
|Clinical Gastroenterology & Hepatology|
The team included randomized, double-blind, placebo-controlled trials evaluating the efficacy of proton pump inhibitors for the treatment of functional dyspepsia.
The investigators calculated relative risk, relative risk reduction and 95% confidence intervals under a random-effects model.
The team identified 7 studies with a total of 3725 patients.
The investigators found that proton pump inhibitors were more effective than placebo for reducing symptoms in patients with functional dyspepsia.
The estimated number needed to treat was 15.
When stratified analyses were performed, the team observed a significant difference in the efficacy only in patients with ulcer-like and reflux-like dyspepsia.
However, there was no difference in the efficacy between PPI use and placebo in those with dysmotility-like and unspecified dyspepsia.
The investigators reported that the effect of H pylori on the efficacy of proton pump inhibitors remains unclear.
The team found significant heterogeneity among studies for the overall analysis, and of dysmotility-like dyspepsia.
In addition, the team observed heterogeneity among H pylori-negative subgroup, and different dose subgroup analyses.
Dr Wang's team commented, “Proton pump inhibitors are more effective than placebo for the management of patients with ulcer-like and reflux-like functional dyspepsia.”